


Investor Presentation Sept. 2023



Safe Harbor Statement



This presentation contains comments and forward-looking statements based upon current plans, expectations, events, and financial and industry trends, which may affect the Company's future operating results and financial position. Such statements involve risks and uncertainties which cannot be predicted or quantified, and may cause future activities or results of operations to differ materially from those discussed herein. Historical results achieved are not necessarily indicative of future profits of the Company. For further information, refer to the Company's filings with the SEC.

Taro occasionally uses numerical measures in investor presentations and other forums which are considered non-GAAP Financial Measures. The Company believes that the presentation of non-GAAP measures, in combination with comparable GAAP measures, together provide our investor community with useful supplementary information concerning the Company's ongoing operations and are an appropriate way to evaluate the company's performance. However, they are provided for informational purposes only.

Forward-looking statements are applicable only as of the date on which they are made. The Company undertakes no obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.

Vision



<u>Reaching People</u> and <u>Touching Lives</u> Globally as a Leading Provider of Valued Medicines.



Company Overview

Fully Integrated Pharmaceutical Company



Research-based, multinational pharmaceutical company

- Predominantly US driven business (90% of sales in North America)
 - Diverse portfolio of 200+ pharmaceutical products
 - Generic Rx and OTC
 - Key therapeutic categories: dermatological/topical, neuropsychiatric, cardiovascular, and anti-inflammatory
- **Operations in the U.S., Canada and Israel with 1,500+ employees worldwide**
 - □ 35% of employees in R&D and Quality
- Market Share
 - Ranked #1 or #2 in 65% by market share in the U.S. generic market
- Excellent track record with FDA & Other Agencies
 - Fully Compliant FDA, Ministry of Health, Health Canada
 - Vertical Integration of API and formulation of select key products
- Financial
 - □ Sun Ownership: 78.5%
 - Strong Balance Sheet
 - **\$1.3 billion** in cash and marketable securities: -0- debt
 - High margins, strong cash generation from operations



Company Overview

Key Dates in Taro History



- **1950** Established in Israel to manufacture finished pharmaceutical products
- **1961** Started chemical synthesis (API production) in Israel
- **1984** Established topical product operations in Canada
- 1988 Entered U.S. market
- 2010 Sun Pharma acquires controlling interest in Taro
- 2012 NYSE Listed
- 2019 Exited branded presence in U.S.
- 2022 Alchemee Acquisition
- 2023 Sun Pharma announces proposal to acquire all of Taro's outstanding ordinary shares

TARC

Share Repurchases:

- 2013 \$193M (Dutch Tender): 2.0M shares
- 2016/2017 \$500M (10b5-1): 4.3M shares
- 2019 \$300M announced:
 - 2019 \$25M (Dutch Tender): 281K shares
 - 2021 \$50M (10b5-1): 673K shares

Special Dividend:

2018 – \$500M: \$12.86 per share




Strategy and Opportunity

Complex, niche products



CREATE SUSTAINABLE REVENUE STREAMS

- Differentiation: Technically complex products
- Regulatory barriers to entry
- Speed to market



COST LEADERSHIP

- Vertical integration : Development through Manufacturing (API and Finished Dosage)
- Optimize operational costs

BALANCE PROFITABILITY AND INVESTMENTS FOR FUTURE

- Development of complex generics
- Growth both organically and through strategic business development

Research Strategy

Technically complex products, Regulatory barriers to entry

Current State (9/30/23)


- 234 Approved US FDA ANDAs
- **D** 19 ANDAs awaiting FDA approval

Generic products with sustainable profitability

- Topicals and other niche products with high clinical and regulatory barriers to entry
- Technically complex manufacturing
- Opportunity for API synthesis
- Proprietary products
 - Innovative products for unmet needs
 - Niche markets mainly in dermatology

Chemical Synthesis/API

- **Developing and manufacturing for most of our top products**
- **D** 60 Drug Master Files (DMFs) currently submitted to FDA






Research & Development

Investing for the future – \$290 million over 5 years








TARO

ANDA Filings

Growing our pipeline of quality products





Note: ANDA Filings are presented on a cumulative basis since 1978.

ANDA Approvals

Strong success in approvals

TARO



Note: ANDA Approvals are presented on a cumulative basis since 1978.

Haifa, Israel Manufacturing, Research, Marketing & Distribution



11

- Fully Compliant Approved by FDA, IMH and Accreditation of foreign manufacturing
- API Development and Manufacturing
- 900,000 sq. ft. manufacturing facility
- 700+ employees
- 100+ finished dosage forms/250+ products manufactured
 - Focus: oral solids, liquids, semi-solids and foams
 - Therapeutic Areas Dermatology, Pain, Gastro, Cardiology and Dental

Primary product lines:

- Dermatology: Rx and OTC semi-solid and liquid products (creams, ointments, lotions & gels)
- Cardiology and Neurology: Prescription oral dosage products
- Gastroenterology: Rx and OTC (Nexium, Normalax & Meroken)
- Oral analgesics: Rx and OTC
- Oral Central Nervous System (CNS): Rx
- OTC nasal sprays
- Allergy (Antihistamine): OTC oral dosage products



+\$46M in sales

Brampton, Canada

Manufacturing, Research, Marketing & Distribution



Fully Compliant – Approved by FDA and Health Canada

Manufactures 200+ finished dosage form pharmaceutical products

Focus: semi-solids and liquids

Primary product lines:

- Dermatology: Rx and OTC semi-solid products (creams, ointments and gels) and liquids
- Injectables and specialty products
- Solid-oral generic medicines

Ranked #6 in the Canadian generic market

- 160+ products sold in Canada
- **245,000+ sq. ft. manufacturing facility**
- 500+ Employees
- +\$136M in sales



U.S. Operations

Headquarters and Distribution Center



13

- HAWTHORNE, NEW YORK -Headquarters 130+ Employees - CRANBURY, NEW JERSEY -Distribution Center 300,000 sq. ft. SOLAR POWERED











14

- Headquarters Hawthorne, New York
 130+ employees
- **Distribution Center Cranbury, New Jersey**
 - **a** 300,000 sq. ft.
 - Solar powered
- Marketing and distribution of generic products in the U.S. market
- Dermatology: Rx, OTC and Proactiv, semisolid products (creams, ointments & gels) and liquids
- □ \$363M in sales

Taro USA Top 10 Products	MAT September Sales USD \$MM							
Tretinoin(Base) Cream	\$51.6							
Clindamycin(Phosphate) Lotion	\$14.8							
Warfarin(Sodium Salt) Tabs	\$14.8							
Mupirocin(Base) Ointment	\$14.7							
Fluorouracil(Base) Cream	\$14.2							
Dapsone(Base) Gel	\$14.2							
Metronidazole(Base) Gel	\$14.1							
Betamethasone(Dipropionate) Cream	\$12.9							
Enalapril(Maleate) Tabs	\$12.3							
Phenytoin(Sodium Salt) Caps	\$12.3							

Source: IQVIA MAT Sept. 2023

Alchemee Acquisition

Topical skin care products





In Feb. 2022, Taro acquired the Proactiv business and product line.

- Proactiv is a line of topical skin care products with a core acne indication: the products include cleansers and moisturizers as well as acne creams.
- A majority of Proactiv sales occur through a subscription model, whereby customers receive monthly shipments of products suited to their individual skin types and needs. Proactiv also sells its products to retailers such as Target and on Amazon.

Acquisition Rationale

- Taro identified four key benefits from the Proactiv acquisition.
 - Expansion of consumer health business
 - Enhanced branded consumer health business
 - Strengthened leadership position in dermatology: Taro is elevated to a top 5 position in topical dermatology in the US consumer health market.
 - **D** Creation of a comprehensive acne portfolio within the Sun group

Proactiv Product


- The original Proactiv 3-step skin care routine was dermatologist-developed and launched in 1995. It has tremendous brand awareness especially in the USA and Japan.
- Proactiv has evolved from a single product direct-response company to a diversified, omni-channel platform. It is sold direct-to-consumer, as well as, in brick & mortar stores like Ulta, Target and CVS, and on e-Retailer sites like Amazon.
- Proactiv has a wide range of products beyond its well-known kits, ranging from Clear Skin SPF 30, Hydrocolloid Blemish Patches, Post Acne Dark Mark Relief and Post Acne Scar Gel.
- In July 2023, Proactiv launched its newest skin care routine "Proactiv Clean," a clean and gentle routine that smooths and helps calm skin while clearing mild breakouts. It features mineral sulfur and salicylic acids with azelaic acid, bakuchiol and chamomile, and formulated without parabens, phthalates, sulfates, cyclic silicones.

Net Sales Composition North America and Derm Focused



16

Source: Taro 2023 Form 20-F



Strong presence in U.S. distribution channels




- Major U.S. drug wholesalers, smaller wholesalers and distributors
- All major retail pharmacy and food chains
- All major mass merchandisers
- Integrated health organizations
 - Pharmacy Benefit Managers (PBMs)
 - Group Purchasing Organizations (GPOs)
 - Long-Term Care Providers (LTCs)
 - Health Maintenance Organizations (HMOs)
- Institutions
- Government
 - V.A., State Medicaid formularies, others

Key Financial Ratios

Full-year results




EBITDA margin *



- FY20/21 & FY21/22 excludes settlement and loss contingency charges.
- YTD 2024 = 4/1/23 to 9/30/23

Net margin *



Earnings per share *





Taro Income Statement

Current 6 month and full year comparisons



(In thousands)

	Six Months E	nded Sept. 30,	Year Ended March 31,											
	As Reported 2023 (unaudited)	As Reported 2022 (unaudited)	As Reported 2023 (audited)	As Reported 2022 (audited)	Proforma 2022 (uncnudited)	As Reported 2021 (audited)	Proforma 2021 (uncnudited)							
Sales, net	\$ 307,096	\$ 287,163	\$ 572,952	\$ 561,347	\$ 561,347	\$ 548,970	\$ 548,970							
Cost of sales	169,410	158,595	304,629	268,212	268,212	252,314	252,314							
Gross profit	137,686	128,568	268,323	293,122	293,122	296,656	296,656							
Operating Expenses:														
Research and development	30,470	23,030	52,243	54,540	54,540	60,152	60,152							
Selling, marketing, general and administrative	110,398	98,377	198,366	113,676	113,676	91,355	91,355							
Settlements and loss contingencies	_	_	_	61,446	_	558,924	_							
Operating income (loss)	(3,182)	7,161	17,714	63,460	124,906	(413,775)	145,149							
Financial (income) expense, net:														
Interest and other financial income	(24,862)	(6,221)	(20,850)	(8,187)	(8,187)	(20,174)	(20,174)							
Foreign exchange expense (income)	(460)	3,082	2,813	(1,986)	(1,986)	365	365							
Other gain, net	956	840	2,463	4,226	4,226	2,892	2,892							
Income (loss) before income taxes	23,096	11,140	38,213	77,859	139,305	(391,073)	167,851							
Tax expense (benefit)	4,515	(126)	12,768	19,592	12,901	9,667	26,380							
Net income (loss)	18,581	11,266	25,445	58,267	126,404	(400,740)	141,471							
Net (loss) income attributable to non-controlling interest						(14,087)	80							
Net income (loss) attributable to Taro	\$ 18,581	\$ 11,266	\$ 25,445	\$ 58,267	\$ 126,404	\$ (386,653)	\$ 141,391							



Balance Sheet Highlights

Strong Balance Sheet - Cash (\$1.3 billion), No Debt



20 (In thousands) Sept 30. March 31. March 31, March 31, 2023 2023 2022 2021 ASSETS CURRENT ASSETS: s 269.011 s 154,495 S 251.134 s Cash and cash equivalents 605,177 Short-term and current maturities of long-term bank deposits 119,980 119,980 47,586 Marketable securities 518,058 575,814 522,028 418,480 RANSPARENCY Accounts receivable and other: 213,539 Trade, net 181.064 202.260 246.973 Other receivables and prepaid expenses 46,254 57,210 59,726 53,347 **CCOUNTABILITY** Inventories 208,188 226,669 210.439 180.292 TOTAL CURRENT ASSETS 1.342,555 1.336,428 1.337,886 1.470.835 Marketable securities 388,370 404,896 435,189 557.209 ESPONSIBILITY Property, plant and equipment, net 189,893 190,139 199,692 205,508 Deferred income taxes 100.807 103.672 124.882 142,007 Goodwill PENNESS 17.231 17.231 11.820 7.191 Other assets 80.617 83,147 66,892 24,123 TOTAL ASSETS S 2.119.473 \$ 2.135.513 S 2.176.361 \$ 2,406,873 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Trade payables S 43,059 s 68,485 s 68,232 s 61,166 Dedicated to maintaining the Other current liabilities 318,429 317.064 363.887 615.135 TOTAL CURRENT LIABILITIES 361,488 385,549 432,119 676,301 highest standards of quality, Deferred taxes and other long-term liabilities 10,429 19,106 32,799 35,115 safety, and excellence. TOTAL LIABILITIES 371.917 711,416 404,655 464,918 Taro shareholders' equity 1,730,858 1,703,649 1,747,556 1,711,443 Non-controlling interest (8,192) TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY \$ 2.119.473 \$ 2.135.513 \$ 2.176.361 \$ 2,406,873

Cash Flow

Significant Cash Flow Generation

21

(In thousands)

Six Months Ended Sept 30,					Year Ended March 31,													
As	Reported 2023				As Reported 2023		Proforma 2023		As Reported 2022		Proforma 2022		As Reported 2021			Proforma 2021		
S	18,581	S	11,266		s	25,445	\$	25,312	\$	58,266	\$	126,404	\$	(400,740)	\$	141,391		
•	36,712	•	(48,933)			6,305		73,730		(216,964)		39,214		446,510		(11,164)		
	55,293		(37,667)			31,750		99,042		(158,698)		165,618		45,770		130,30 7		
	59,866		(36,039)			(125,556)		(125,556)		(170,581)		(78,709)		67,741		67,741		
	_		_			_		_		(24,934)		(24,934)		(24,196)		(24,196)		
	114,516		(75,943)			(96,639)		(29,347)		(354,043)		62,145		91,823		91,823		
	154,495		251,134			251,134		251,134		605,177		605,177		513,354		513,354		
\$	269,011	\$	175,191		\$	154,495	\$	221,787	\$	251,134	\$	667,322	\$	605,177	\$	605,177		
		As Reported 2023 \$ 18,581 36,712 55,293 59,866 	As Reported 2023 As 2023 \$ 18,581 \$ 36,712 55,293 \$ 59,866 114,516 154,495	As Reported 2023 As Reported 2022 \$ 18,581 \$ 11,266 36,712 (48,933) 55,293 (37,667) 59,866 (36,039) - - 114,516 (75,943) 154,495 251,134	As Reported 2023 As Reported 2022 \$ 18,581 \$ 11,266 36,712 (48,933) 55,293 (37,667) 59,866 (36,039) 114,516 (75,943) 154,495 251,134	As Reported 2023 As Reported 2022 As \$ 18,581 \$ 11,266 \$ 36,712 (48,933) \$ 55,293 (37,667) \$ 114,516 (75,943) \$ 154,495 251,134 \$	As Reported 2023 As Reported 2022 As Reported 2023 \$ 18,581 \$ 11,266 \$ 25,445 36,712 (48,933) 6,305 55,293 (37,667) 31,750 59,866 (36,039) (125,556) 114,516 (75,943) (96,639) 154,495 251,134 251,134	As Reported 2023 As Reported 2022 As Reported 2023 As Reported 2023 \$ 18,581 \$ 11,266 \$ 25,445 \$ 36,712 \$ (48,933) \$ 6,305 55,293 (37,667) 31,750 59,866 (36,039) (125,556) 114,516 (75,943) (96,639) 154,495 251,134 251,134	As Reported 2023 As Reported 2022 As Reported 2023 Proforma 2023 \$ 18,581 \$ 11,266 \$ 25,445 \$ 25,312 36,712 (48,933) 6,305 73,730 55,293 (37,667) 31,750 99,042 59,866 (36,039) (125,556) (125,556) 114,516 (75,943) (96,639) (29,347) 154,495 251,134 251,134 251,134	As Reported 2023 As Reported 2022 As Reported 2023 Proforma 2023 A \$ 18,581 \$ 11,266 \$ 25,445 \$ 25,312 \$ 36,712 (48,933) 6,305 73,730 \$ 59,866 (36,039) (125,556) (125,556) \$ 114,516 (75,943) (96,639) (29,347) \$ 154,495 251,134 251,134 251,134 \$	As Reported 2023 As Reported 2022 As Reported 2023 Proforma 2023 As Reported 2023 \$ 18,581 \$ 11,266 \$ 25,445 \$ 25,312 \$ 58,266 36,712 (48,933) 6,305 73,730 (216,964) 55,293 (37,667) 31,750 99,042 (158,698) 59,866 (36,039) (125,556) (170,581) - - - (24,934) 114,516 (75,943) (96,639) (29,347) (354,043) 154,495 251,134 251,134 251,134 605,177	As Reported 2023 As Reported 2022 As Reported 2023 Proforma 2023 As Reported 2023 Proforma 2023 As Reported 2023 Proforma 2023 As Reported 2022 Proforma 2023 As Reported 2022 Proforma 2023 As Reported 2023 Proforma 2023 As Reported 2023 Proforma 2023 As Reported 2023 Proforma 2023 As Reported 2023 Proforma 2023 Profor	As Reported 2023 As Reported 2022 As Reported 2023 Profoma 2023 As Reported 2023 Profoma 2023 Profoma 2022 Profoma 2022 Profoma 2022 \$ 18,581 \$ 11,266 \$ 25,445 \$ 25,312 \$ 58,266 \$ 126,404 36,712 (48,933) 6,305 73,730 (216,964) 39,214 55,293 (37,667) 31,750 99,042 (158,698) 165,618 59,866 (36,039) (125,556) (125,556) (170,581) (78,709) - - - - (24,934) (24,934) 114,516 (75,943) (96,639) (29,347) (354,043) 62,145 154,495 251,134 251,134 251,134 605,177 605,177	As Reported 2023 As Reported 2023 As Reported 2023 Proforma 2023 As Reported 2023 Proforma 2023 As Reported 2023 Proforma 2022 As Reported 2023 Proforma 2022 As Reported 2023 Proforma 2022 As Reported 2023 Proforma 2023 As Reported 2023 Proforma 2022 As Reported 2023 Proforma 2023 As Reported 2023 Proforma 2023 As Reported 2023 As Reported 2023 Proforma 2023 As Reported 2023 Proforma 2023 As Reported 2023 As Reported	As Reported 2023 As Reported 2022 As Reported 2023 Proforma 2023 As Reported 2023 Proforma 2023 Proforma 2022 Proforma 2022 As Reported 2022 As Reported 2021 Description 2021 \$ 18,581 \$ 11,266 \$ 25,445 \$ 25,312 \$ 58,266 \$ 126,404 \$ (400,740) 36,712 (48,933) 6,305 73,730 (216,964) 39,214 446,510 59,866 (36,039) (125,556) (125,556) (170,581) (78,709) 67,741 - - - - (24,934) (24,934) (24,196) 114,516 (75,943) (96,639) (29,347) (354,043) 62,145 91,823 154,495 251,134 251,134 251,134 605,177 605,177 513,354	As Reported 2023 As Reported 2022 As Reported 2023 Proforma 2023 As Reported 2023 Proforma 2022 Proforma 2022 As Reported 2021 Operation \$ 18,581 \$ 11,266 \$ 25,445 \$ 25,312 \$ 58,266 \$ 126,404 \$ (400,740) \$ 36,712 (48,933) 6,305 73,730 (216,964) 39,214 446,510 59,866 (36,039) (125,556) (125,556) (170,581) (78,709) 67,741 - - - (24,934) (24,934) (24,196) 114,516 (75,943) (96,639) (29,347) (354,043) 62,145 91,823 154,495 251,134 251,134 251,134 605,177 605,177 513,354		





Taro Summary Overview



Shareholder value creation

- NYSE Listed in 2012
- Special Dividend: \$500 million (\$12.86/share)
- Share Repurchases:
 - **2013** Dutch Tender: 2.0M shares (\$193M)
 - 2016 10b5-1: 1.8M shares (\$250M)
 - **2019** 10b5-1: 2.5M shares (\$250M)
 - **2019** Dutch Tender: 281K shares (\$25M)
 - **2021** 10b5-1; 673K shares (\$50M)
- Cash and cash equivalents (including bank deposits and short-term/long-term marketable securities)
 \$1.3 billion
- **Company well positioned for medium & long-term performance**



Thank You!

NYSE: TARO

www.taro.com

